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SUMMARY
Background
The goal of hepatorenal syndrome type 1 (HRS-1) treatment is to improve
renal function. Terlipressin, a synthetic vasopressin analogue, is a systemic
vasoconstrictor used for the treatment of HRS-1, where it is available.
Aim
To compare the efﬁcacy of terlipressin plus albumin vs. placebo plus albu-
min in patients with HRS-1.
Methods
Pooled patient-level data from two large phase 3, randomised, placebo-con-
trolled studies were analysed for HRS reversal [serum creatinine (SCr) value
≤133 lmol/L], 90-day survival, need for renal replacement therapy and pre-
dictors of HRS reversal. Patients received intravenous terlipressin 1–2 mg
every 6 hours plus albumin or placebo plus albumin up to 14 days.
Results
The pooled analysis comprised 308 patients (terlipressin: n = 153; placebo:
n = 155). HRS reversal was signiﬁcantly more frequent with terlipressin vs.
placebo (27% vs. 14%; P = 0.004). Terlipressin was associated with a more
signiﬁcant improvement in renal function from baseline until end of treat-
ment, with a mean between-group difference in SCr concentration of
53.0 lmol/L (P < 0.0001). Lower SCr, lower mean arterial pressure and
lower total bilirubin and absence of known precipitating factors for HRS
were independent predictors of HRS reversal and longer survival in terli-
pressin-treated patients.
Conclusions
Terlipressin plus albumin resulted in a signiﬁcantly higher rate of HRS
reversal vs. albumin alone in patients with HRS-1. Terlipressin treatment is
associated with improved renal function. (ClinicalTrials.gov identiﬁer:
OT-0401, NCT00089570; REVERSE, NCT01143246).
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INTRODUCTION
Hepatorenal syndrome type 1 (HRS-1) is a rapidly pro-
gressive but potentially reversible form of renal failure
that may develop in patients with cirrhosis and ascites,
acute liver failure, or alcoholic hepatitis.1 In patients with
HRS-1, serum creatinine (SCr) increases to >226 lmol/L
within 2 weeks, frequently after a precipitating event,
such as an infection or gastrointestinal bleeding.1, 2
Renal failure develops subsequent to a series of pathophys-
iologic haemodynamic changes. Splanchnic arterial
vasodilation consequent upon the presence of portal
hypertension leads to a reduction in effective arterial blood
volume. This in turns activates the renin-angiotensin-
aldosterone system and the sympathetic nervous system,
resulting in intense renal vasoconstriction and a reduction
in the glomerular ﬁltration rate (GFR), followed by renal
sodium and water retention, which ultimately leads to
ascites and oedema.3
Without effective treatment, HRS-1 is rapidly fatal,
with a median survival of 1 month.4 The deﬁnitive ther-
apy for HRS-1 is liver transplantation, which eliminates
the liver dysfunction, portal hypertension, and splanch-
nic arterial vasodilation that led to the renal conse-
quences.5 The presence of renal insufﬁciency at the time
of liver transplantation may reduce post-transplant sur-
vival.6–9 In addition, liver transplantation is not possible
for all patients with HRS-1. Current recommended ﬁrst-
line therapies for HRS-1 are vasoconstrictors coupled
with albumin; among the vasoconstrictors, terlipressin is
recommended in clinical practice guidelines as ﬁrst-line
therapy for HRS-1, where it is available.10 Terlipressin is
a synthetic vasopressin analogue that produces systemic
vasoconstriction through its V1 receptor agonist activ-
ity.11 In several small, randomised, controlled studies,
terlipressin treatment was shown to improve renal func-
tion in patients with HRS-1 by signiﬁcantly reducing
SCr.12–16 Meta-analyses of these studies of terlipressin in
HRS-1 support the beneﬁcial effect of terlipressin on
renal function.17, 18
OT-0401 and REVERSE are two large, similarly
designed phase 3 clinical studies comparing treatment
with terlipressin plus albumin vs. placebo plus albumin
in patients with HRS-1. Given the very limited sample
sizes in the majority of previously published studies in
this therapeutic area, a pooled analysis of individual
patient-level data from these two studies was performed
to assess the effects of terlipressin in the overall popula-
tion and allow a robust analysis of predictive factors
using a large database. Here, we present the results of
the pooled analysis of the OT-0401 and REVERSE
studies.
MATERIALS AND METHODS
The study designs, including eligibility criteria, proce-
dures, treatments and statistical analyses, have been
reported previously.11, 16, 19
Patients
Brieﬂy, eligible patients in both studies were aged
18 years or older and had a diagnosis of HRS-1. In the
OT-0401 study, the diagnosis was based on the 1996
International Club of Ascites criteria.20 In the REVERSE
study, the diagnosis was based on International Club of
Ascites criteria, which were updated in 2007.1 The OT-
0401 study comprised patients with chronic liver disease
or acute (de novo onset within 6 weeks) viral and/or
alcoholic hepatitis, and the REVERSE study comprised
patients with cirrhosis and ascites, with or without
superimposed alcoholic hepatitis.
All patients were required to have rapidly progressive
reduction in renal function. In the OT-0401 study,
reduction in renal function was deﬁned as a doubling of
SCr to ≥226 lmol/L within 2 weeks or a 50% reduction
in the initial 24-h creatinine clearance to <20 mL/min in
the absence of other causes of renal impairment. In the
REVERSE study, reduction in renal function was deﬁned
as SCr ≥226 lmol/L and/or a doubling of SCr within
2 weeks.
Both studies required that patients have no sustained
improvement in renal function during the pre-enrolment
screening phase. However, in the REVERSE study, these
criteria were extended and reﬁned; all patients under-
went ﬂuid challenge with intravenous albumin to
demonstrate that volume expansion was insufﬁcient to
correct renal failure, and speciﬁc inclusion criteria were
applied for the SCr response 48 h after diuretic with-
drawal and albumin administration (<20% decrease in
SCr and SCr ≥199 lmol/L) to avoid enroling patients
who quickly responded to albumin alone.
The OT-0401 study had no upper limit of baseline
SCr values for patient exclusion; the REVERSE study
excluded patients with SCr values ≥619 lmol/L based on
the absence of response in these patients observed in the
OT-0401 study. Both studies excluded patients with
ongoing shock or uncontrolled bacterial infection.
Patients receiving octreotide, midodrine, vasopressin,
dopamine or other vasopressors within 48 h, as well as
patients who received <2 days of anti-infective therapy
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for suspected or documented infection, were excluded in
the REVERSE study.
Study design
OT-0401 (NCT00089570) and REVERSE (NCT01143246)
were phase 3, multicentre, randomised, double-blind, pla-
cebo-controlled studies. OT-0401 was conducted at 35
medical centres across the USA (n = 30), Germany
(n = 2) and Russia (n = 3) from June 2004 through
September 2006.19 REVERSE was conducted at 52 medical
centres in the USA (n = 50) and Canada (n = 2) during
October 2010 through February 201316; eligible patients
were randomised (1:1) to receive terlipressin or placebo,
stratiﬁed by presence or absence of alcoholic hepatitis (see
Supporting Information for a complete list of the OT-
0401 and REVERSE investigators). REVERSE also strati-
ﬁed patients by SCr <318 lmol/L or ≥318 lmol/L, based
on the identiﬁcation of lower baseline SCr as a predictor
of HRS reversal and survival observed in the OT-0401
study. Concomitant use of albumin was strongly recom-
mended for the two treatment arms in both studies if clin-
ically appropriate (OT-0401: 100 g on day 1 and 25 g
daily until end of treatment; REVERSE: 20–40 g/day).
OT-0401 and REVERSE included three periods: pre-
study, 14-day active treatment, and 180-day (OT-0401)
and 90-day (REVERSE) follow-up. Both studies were con-
ducted in accordance with the ethical principles of the
Declaration of Helsinki and were in compliance with good
clinical practice and all applicable regulatory guidelines.
The protocols were approved by an institutional review
board and/or independent ethics committee at each study
site, and all patients or their surrogates provided written
informed consent.
In both studies, slow intravenous bolus injections of
terlipressin or placebo were administered over 2 min
four times daily. A terlipressin starting dose of 1 mg
every 6 h (4 mg/day) could be doubled to 2 mg every
6 h (8 mg/day) in patients who achieved a < 30%
decrease in SCr after either a minimum of 12 doses
(OT-0401) or a minimum of 10 doses (REVERSE). How-
ever, the REVERSE study did not permit dose escalation
in patients with known coronary artery disease or in the
clinical setting of circulatory overload, pulmonary
oedema or treatment-refractory bronchospasm. In addi-
tion, both studies required permanent discontinuation in
the case of renal replacement therapy or liver transplan-
tation, or if SCr remained at or above baseline either on
day 4 after a minimum of 10 doses (REVERSE) or on
day 7 or later (OT-0401); dosing could be interrupted
for an adverse event and then decreased to a lower dose
(0.5 mg every 6 h). In OT-0401, a less frequent dosing
interval (1 mg every 8–12 h) could be resumed. Inter-
ruption for an ischaemic adverse event mandated perma-
nent discontinuation in REVERSE. Study medication was
continued for 2 days after a ﬁrst value of SCr
<133 lmol/L had been obtained or up to a maximum of
14 days in either study.
The primary endpoint in the OT-0401 study was
treatment success at day 14, deﬁned as SCr <133 lmol/L
on two occasions at least 48 (8) h apart, followed by
an additional SCr value <226 lmol/L measured on day
14, without intervening liver transplant, dialysis or HRS
recurrence. The primary endpoint of the REVERSE study
was conﬁrmed HRS reversal, deﬁned as at least two
on-treatment SCr values <133 lmol/L at least 48 (8) h
apart and without intervening renal replacement therapy
or liver transplant.
Pooled analysis
HRS reversal was chosen as the main outcome of interest
for the pooled analysis because its deﬁnition was identi-
cal in OT-0401 and REVERSE. In each study, the inci-
dence of HRS reversal was deﬁned as the percentage of
patients with at least one SCr value <133 lmol/L on
treatment (up to 24 h after the last dose of study medi-
cation). Other parameters assessed for the current analy-
sis included change from baseline in SCr, estimated GFR
(eGFR) (calculated using the Cockcroft-Gault equation),
and mean arterial pressure (MAP), as well as transplant-
free survival, overall survival and use of renal replace-
ment therapy.
Statistical analyses
The intent-to-treat (ITT) population, deﬁned as all ran-
domised patients who had at least one baseline assess-
ment, was used in the pooled analysis. Differences
between treatment groups in the incidence of HRS rever-
sal were analysed with the Cochran-Mantel-Haenszel test
for general association adjusted for alcoholic hepatitis
(present or not present).
To evaluate changes from baseline in SCr and eGFR,
least-squares (LS) means were calculated from repeated-
measures analysis of variance, with factors of treatment,
alcoholic hepatitis, day and treatment by day interaction
in the pooled analysis. The LS mean treatment difference
between groups was calculated as the terlipressin LS
mean change from baseline minus the placebo LS mean
change from baseline. MAP changes were evaluated with
an analysis of variance comparing the change from base-
line values.
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The estimated transplant-free survival and overall sur-
vival rates were compared with P values derived from a
two-sample log-rank test stratiﬁed by alcoholic hepatitis
(present or not present).
Baseline prognostic factors were evaluated by univari-
ate and multivariate logistic regression analysis. For mul-
tivariate analyses, two models with a combination of
four baseline variables and one model with a combina-
tion of three baseline variables were used; for each analy-
sis, all signiﬁcant univariate results were added to the
model, and step-wise selection was used to obtain the
ﬁnal model.
RESULTS
Patients
The pooled analysis population comprised 308 patients
(terlipressin plus albumin: n = 153; placebo plus albu-
min: n = 155). The baseline patient disposition for both
studies is shown in Figure 1. Overall, baseline patient
demographic and clinical characteristics were typical of a
severely ill HRS-1 population (>60% Child–Pugh Class
C, mean baseline Model for End-Stage Liver Disease
[MELD] scores of 32–34, and >90% with ascites) and
were generally similar between treatment groups
(Table 1).
Treatment
Mean duration of treatment was 6.1 days in the terli-
pressin and placebo groups, and mean total exposure to
study drug was 26.2 mg with terlipressin and 27.6 mg
with placebo. The standard dose level (1 mg) was used
by 73% (112/153) of patients receiving terlipressin and
64% (99/155) of patients receiving placebo, while a high
dose level (at least one 2-mg dose) was used by 24% (37/
153) and 33% (51/155) of patients, respectively. The pro-
portion of patients with concomitant albumin use from
the start to the end of treatment was similar between
groups [terlipressin: 87.6% (134/153); placebo: 87.1%
(135/155)]. Mean duration of concomitant albumin use
was 4.9 days and total exposure to concomitant albumin
was 225 g in patients receiving terlipressin and 5.5 days
and 244 g, respectively, in patients receiving placebo
(P = NS).
Changes in renal function
As shown in Figure 2, the incidence of HRS reversal was
signiﬁcantly higher among patients receiving terlipressin
[42/153 (27%)] compared with patients receiving placebo
[22/155 (14%); P = 0.004]. In the pooled analysis, mean
(standard deviation) time from randomisation to HRS
reversal was 6.6 (3.5) days in patients receiving terli-
pressin and 6.4 (3.2) days in patients receiving placebo.
A sensitivity analysis was performed to determine the
generalisability of the data. The incidence of HRS rever-
sal in subgroup analyses was generally higher among
patients receiving terlipressin compared with those
receiving placebo; however, when analysed by gender,
HRS reversal was achieved by 29% of male patients
receiving terlipressin vs. 13% receiving placebo
(P = 0.006) but only by 25% of female patients receiving
terlipressin vs. 16% receiving placebo (P = 0.27). Terli-
pressin treatment resulted in higher rates of HRS reversal
vs. placebo in patients with less severe disease, such as
those with baseline SCr <265 lmol/L (47% vs. 21%;
P = 0.008), lower (<34) baseline MELD score (42% vs.
17%; P = 0.0008), and baseline MAP ≥70 mmHg (27%
vs. 12%; P = 0.008). The incidence of HRS reversal in
patients with Child–Pugh Class C disease was signiﬁ-
cantly higher with terlipressin vs. placebo (28% vs. 12%;
P = 0.005). In patients receiving >10 doses of study
medication, the incidence of HRS reversal was approxi-
mately twofold greater with terlipressin vs. placebo (43%
vs. 20%; P = 0.0004), as was the incidence of HRS rever-
sal in patients who received >12 doses of study medica-
tion (50% vs. 26%; P = 0.0013); however, these results
could have been confounded because dosing could be
discontinued if patients did not demonstrate early
response to study drug. The incidence of HRS reversal in
patients with dose increases also was signiﬁcantly higher
with terlipressin vs. placebo (32% vs. 10%; P = 0.008).
The repeated-measures LS mean changes in SCr con-
centration from baseline to the end of treatment are
shown in Figure 3. The SCr concentration decreased
over time in the terlipressin and placebo groups, with a
mean treatment difference between groups of
53.0 lmol/L (P < 0.0001) in the pooled analysis; the
mean between-group difference also was signiﬁcant in
the individual studies. In addition, eGFR increased over
time in both groups and was signiﬁcantly greater with
terlipressin (28.0 mL/min) vs. placebo (13.8 mL/min) in
the pooled analysis, for a repeated-measures LS mean
between-group difference of 14.2 mL/min (P < 0.0001);
the mean treatment difference between groups in the
individual studies was also signiﬁcant.
Mean arterial pressure
From baseline to the end of treatment, MAP increased
by 4.1 mmHg in patients receiving terlipressin and
decreased by 1.8 mmHg in patients receiving placebo in
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112 patients enrolled and 
randomized to study treatment
56 randomized to terlipressin 56 randomized to placebo
56 received terlipressin
End of treatment
• 40 alive
• 16 dead
0 did not 
receive study drug
1 did not 
receive study drug
55 received placebo
End of treatment
• 39 alive
• 17 dead
30-day follow-up
• 31 alive
• 25 dead
• 0 withdrew consent
30-day follow-up
• 33 alive
• 23 dead
• 1 withdrew consent
60-day follow-up
• 26 alive
• 30 dead
60-day follow-up
• 27 alive
• 29 dead
90-day follow-up
• 24 alive
• 32 dead
90-day follow-up
• 27 alive
• 29 dead
OT-0401 study
196 patients enrolled and 
randomized to study treatment
97 randomized to terlipressin 99 randomized to placebo
93 received terlipressin
End of treatment
• 97 alive
• 0 dead
4 did not 
receive study drug
4 did not 
receive study drug
95 received placebo
End of treatment
• 98 alive
• 1 dead
30-day follow-up
• 68 alive
• 28 dead
• 0 lost to follow-up
• 1 withdrew consent
30-day follow-up
• 65 alive
• 32 dead
• 1 lost to follow-up
• 1 withdrew consent
60-day follow-up
• 53 alive
• 42 dead
• 2 lost to follow-up
• 2 withdrew consent
60-day follow-up
• 61 alive
• 35 dead
• 0 lost to follow-up
• 1 withdrew consent
90-day follow-up/end of study
• 51 alive
• 45 dead
• 1 lost to follow-up
• 1 withdrew consent
90-day follow-up/end of study
• 54 alive
• 42 dead
• 0 lost to follow-up
• 1 withdrew consent
REVERSE study
(a)
(b)
Figure 1 | Patient disposition in the (a) OT-0401 and (b) REVERSE studies. The REVERSE study patient disposition is
reprinted from Gastroenterology, 150, Boyer TD, Sanyal AJ, Wong F, et al., Terlipressin plus albumin is more effective
than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1, 1579–1589,
copyright 2016, with permission from Elsevier.
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the pooled analysis (P = 0.0003). Similar results were
observed for the individual studies.
Survival
In the terlipressin group, 31% (48/153) of patients
received a liver transplant up to day 90 compared with
30% (47/155) in the placebo group; 26% (40/153) in the
terlipressin group and 23% (35/155) in the placebo
group were alive and transplant-free at day 90. No
effects of terlipressin on transplant-free survival or over-
all survival at day 90 were identiﬁed in the pooled analy-
sis (Figure 4a and b). The estimated transplant-free
survival rates at day 90 (death as an event) were 43.8%
in patients receiving terlipressin and 37.9% in patients
receiving placebo (P = 0.7162). The estimated overall
survival rates at day 90 were 54.2% in patients receiving
terlipressin and 49.5% in patients receiving placebo
(P = 0.5588). As shown in Figures 4c and d, both trans-
plant-free and overall survival rates up to 90 days were
signiﬁcantly higher in patients with HRS reversal vs.
those without HRS reversal, regardless of treatment
received (transplant-free survival with terlipressin: 78.7%
vs. 26.0%, P < 0.0001; transplant-free survival with pla-
cebo: 67.0% vs. 31.2%, P = 0.0026; overall survival with
terlipressin: 81.0% vs. 44.1%, P < 0.0001; overall survival
with placebo: 68.2% vs. 46.4%, P = 0.036).
In subgroup analyses, overall survival at day 90 was
signiﬁcantly lower in females vs. males (43.1% vs. 56.7%;
P = 0.021). However, overall survival at 90 days trended
higher in females receiving terlipressin vs. placebo
(50.0% vs. 34.7%; P = 0.0658) and was similar to that in
males (57.0% vs. 56.4%; P = 0.774). Regarding the
assessment of overall survival in other subgroups, a lar-
ger proportion of patients with baseline MAP
Table 1 | Summary of baseline demographics and measures (intent-to-treat population)
OT-0401 + REVERSE
Terlipressin n = 153 Placebo n = 155
Age, years, mean (SD) 53.9 (9.5) 54.2 (9.6)
Female, n (%) 60 (39.2) 49 (31.6)
White, n (%) 136 (88.9) 141 (91.0)
Child–Pugh Class, n (%)
Class A (5–6) 2 (1.3) 1 (0.6)
Class B (7–9) 32 (20.9) 39 (25.2)
Class C (10–15) 109 (71.2) 107 (69.0)
MELD score, mean (SD) 33.4 (6.1) 32.9 (5.8)
Encephalopathy stage, mean (SD) 1.5 (0.8) 1.4 (0.9)
SCr, lmol/L, mean (SD) 327.1 (144.1) 327.1 (97.2)
Alcoholic hepatitis, n (%) 40 (26.1) 45 (29.0)
Possible precipitating factors for HRS, n (%)
Diuretic treatment 25 (16.3) 23 (14.8)
Gastrointestinal bleeding 7 (4.6) 10 (6.5)
Infection 32 (20.9) 29 (18.7)
LVP 23 (15.0) 20 (12.9)
Other 7 (4.6) 13 (8.4)
Cirrhosis due to, n (%)
Alcohol 78 (51.0) 83 (53.5)
Hepatitis B 7 (4.6) 4 (2.6)
Hepatitis C 59 (38.6) 61 (39.4)
Non-alcoholic steatohepatitis 10 (6.5) 12 (7.7)
Autoimmune hepatitis 3 (2.0) 4 (2.6)
Primary biliary cirrhosis 6 (3.9) 4 (2.6)
Hepatocellular carcinoma, n (%) 11 (7.2) 18 (11.6)
Oesophageal varices, n (%) 87 (56.9) 86 (55.5)
Ascites, n (%) 147 (96.1) 146 (94.2)
Mean arterial pressure, mmHg (SD) 75.6 (11.6) 76.1 (11.7)
Concomitant use of beta blockers, n (%) 41 (26.8) 41 (26.5)
Prior rifaximin use, n (%) 72 (47.1) 67 (43.2)
HRS, hepatorenal syndrome; LVP, large volume paracentesis; MELD, model for end-stage liver disease; SCr, serum creatinine; SD,
standard deviation.
Aliment Pharmacol Ther 2017; 45: 1390–1402 1395
ª 2017 The Authors. Alimentary Pharmacology and Therapeutics published by John Wiley & Sons Ltd.
Terlipressin in HRS-1: pooled data from 2 pivotal studies
<70 mmHg who received terlipressin survived vs.
patients who received placebo (71% vs. 41%; P = 0.004).
Patients taking concomitant beta blockers who received
terlipressin also had a signiﬁcantly higher overall survival
rate vs. those who received placebo (70% vs. 39%;
P = 0.036).
Renal replacement therapy
The cumulative incidence of renal replacement therapy
was slightly lower in the terlipressin group than in the
placebo group through day 90 (Figure 5a). By day 90 of
follow-up, 5% (2/42) of patients receiving terlipressin
who experienced HRS reversal required renal replace-
ment therapy compared with 14% (3/22) of patients
receiving placebo. Among patients who did not experi-
ence HRS reversal, renal replacement therapy was
required by 47% (52/111) of patients receiving terli-
pressin and 42% (56/133) receiving placebo. The propor-
tion of patients with HRS reversal who did not require
renal replacement therapy and who were alive at day 90
was 76% (32/42) with terlipressin and 55% (12/22) with
placebo (P = 0.094) (Figure 5b).
Predictive factors for HRS reversal and survival
Baseline factors predictive of HRS reversal by univariate
analysis in the patients treated with terlipressin were
lower international normalised ratio, lower MELD score,
33.9
23.7
27.5
12.5
15.2 14.2
0
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10
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35
40
OT-0401 REVERSE OT-0401 +
REVERSE
Terlipressin
Placebo
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(%
)
*
n = 56 56 97 99 153 155
†
Figure 2 | Incidence of hepatorenal syndrome reversal
in the pooled analysis and in the individual OT-0401
and REVERSE studies. *P = 0.008 vs. placebo.
†P = 0.004 vs. placebo.
Terlipressin (n = 153)
Placebo (n = 155)
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(n = 17)
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P < 0.0001
Figure 3 | Mean change in serum creatinine from baseline to the end of treatment in the pooled analysis of the
OT-0401 and REVERSE studies. LS, least-squares mean; SE, standard error.
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lower SCr and lack of prior use of rifaximin (Table 2).
For transplant-free survival, univariate baseline predic-
tors in patients treated with terlipressin were lower
MELD score, lower SCr, lower MAP and lower bilirubin
and absence of precipitating factors for HRS (Table 3).
Similar to transplant-free survival, lower MELD score,
lower SCr, lower MAP and lower bilirubin and absence
of precipitating factors for HRS were signiﬁcantly predic-
tive of overall survival in terlipressin-treated patients in
the univariate analysis (Table 3).
In the placebo group, no baseline factors were found
to be signiﬁcantly predictive of HRS reversal by univari-
ate analysis; however, there was a non-signiﬁcant trend
for lower baseline MELD score. Absence of alcoholic
hepatitis and male sex were shown to be predictive of
longer transplant-free survival by univariate analysis in
the placebo group; only the absence of alcoholic hepatitis
and male sex were predictive of longer overall survival.
Multiple models were prepared to carry out multivari-
ate analyses to verify the independent predictive value of
the various baseline parameters on HRS reversal, 90-day
transplant-free survival and 90-day overall survival. For
HRS reversal, results from the univariate analysis were
conﬁrmed by the multivariate analyses (see Supporting
Information). For 90-day transplant-free survival, lower
SCr, lower MAP, and lower total bilirubin and absence
of precipitating factors remained independent predictors
of longer transplant-free survival in the terlipressin
group (see Supporting Information). As in the univariate
analysis, absence of alcoholic hepatitis and male sex were
independently predictive of longer transplant-free sur-
vival in the placebo group. Lower SCr, lower MAP, and
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Figure 4 | (a) Transplant-free survival up to 90 days in the overall pooled population from the OT-0401 and REVERSE
studies (intent-to-treat population); (b) overall survival up to 90 days in the overall pooled population from the OT-
0401 and REVERSE studies (intent-to-treat population); (c) transplant-free survival up to 90 days in the pooled
population from the OT-0401 and REVERSE studies stratiﬁed by HRS reversal status and treatment arm; and (d)
overall survival up to 90 days in pooled population from the OT-0401 and REVERSE studies stratiﬁed by HRS reversal
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lower total bilirubin and absence of precipitating factors
were found by multivariate analysis to be independent
predictors of longer overall survival in the terlipressin
group; absence of alcoholic hepatitis and male sex were
independent predictors in the placebo group (see Sup-
porting Information).
Safety
Details regarding the observed safety proﬁles for each
individual study have been previously reported.16, 19
Overall, the incidence of adverse events was similar in
the two treatment groups [terlipressin, 142/149 (95%);
placebo, 137/150 (91%)], as was the incidence of serious
adverse events [terlipressin, 96/149 (64%); placebo, 89/
150 (59%)]. A total of 71 patients (48%) in the terli-
pressin group experienced treatment-related adverse
events compared with 42 (28%) in the placebo group.
The most commonly reported adverse events were
abdominal pain [terlipressin, 36/149 (24%); placebo, 24/
150 (16%)], nausea [terlipressin, 20/149 (13%); placebo,
20/150 (13%)], hypotension [terlipressin, 23/149 (15%);
placebo, 13/150 (9%)], and diarrhoea [terlipressin, 26/
149 (17%); placebo, 6/150 (4%)]. Twenty-two patients
(15%) in the terlipressin group and 8 (5%) in the pla-
cebo group discontinued from the study due to adverse
events.
DISCUSSION
The results of this pooled analysis of individual patient-
level data from the phase 3 OT-0401 and REVERSE
studies demonstrate that the addition of terlipressin to
albumin provides a signiﬁcant beneﬁt in terms of HRS
reversal in patients with HRS-1. The signiﬁcant increase
in the frequency of HRS reversal observed with terli-
pressin is consistent with a signiﬁcant improvement in
renal function, as reﬂected by reductions in SCr and
increases in eGFR. In addition, observed increases from
baseline in MAP with terlipressin treatment are consis-
tent with published ﬁndings of vasoconstrictor therapy
in HRS-1 in which increases in MAP have been associ-
ated with improved clinical outcomes.21
Our ﬁndings also demonstrate the importance of
keeping patients on treatment and minimising with-
drawals due to adverse events, as well as the beneﬁts of
increasing the dose of terlipressin if necessary; subgroup
analyses indicated signiﬁcantly higher rates of HRS
reversal for patients who received >10 and >12 doses of
medication and those who had dose increases. Also, the
need for early recognition and treatment of HRS-1 is
also apparent from these data, as patients did better if
treatment commenced at a lower SCr.
Overall, the observed rates of transplant-free survival
and overall survival up to day 90 were similar in the
two treatment groups. The lack of an effect of terli-
pressin on survival in this pooled analysis is not sur-
prising. Although terlipressin has been shown to
improve renal function, it does not affect the underly-
ing liver disease; therefore, terlipressin would not be
expected to have more than a modest effect on sur-
vival, which would be difﬁcult to demonstrate even in
large studies. For example, in OT-0401 (N = 112), a
relative difference of 14% in overall survival was
observed in favour of terlipressin by the 180-day fol-
low-up visit (42.9% for terlipressin patients vs. 37.5%
for placebo patients; P = 0.839).19 Given the observed
overall relative survival difference of 14%, a much lar-
ger sample size (~2000 patients) would be required to
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Figure 5 | (a) Cumulative incidence of RRT in the
pooled terlipressin and placebo populations from the
OT-0401 and REVERSE studies. (b) Proportion of
patients alive at day 90 with HRS reversal without RRT.
RRT, renal replacement therapy.
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Table 2 | Pooled univariate logistic regression analysis of effects of baseline characteristics on HRS reversal by
treatment group (intent-to-treat population)
Baseline parameter*
Terlipressin Placebo
N RR 95% CI P value N RR 95% CI P value
Age <65 years 153 1.05 0.47–2.34 0.9063 155 0.83 0.27–2.54 0.7465
Alcoholic hepatitis not present 153 0.71 0.42–1.20 0.2021 155 1.09 0.46–2.61 0.8449
Child–Pugh score 143 0.97 0.85–1.10 0.6128 147 0.91 0.73–1.14 0.4009
INR 144 0.61 0.42–0.90 0.0121 148 0.76 0.42–1.36 0.3506
MAP 153 0.99 0.97–1.02 0.6466 154 1.00 0.97–1.04 0.8498
MELD score 138 0.93 0.90–0.97 <0.0001 140 0.94 0.88–1.00 0.0571
Serum creatinine 153 0.61 0.45–0.82 0.0011 155 0.70 0.46–1.05 0.0843
Serum sodium 153 1.00 0.97–1.04 0.8905 155 1.00 0.95–1.07 0.8738
Total bilirubin 150 0.98 0.95–1.01 0.1258 150 0.98 0.94–1.01 0.2294
Male sex 153 1.16 0.68–2.00 0.5882 155 0.81 0.36–1.80 0.6035
Precipitating factor for HRS 153 0.79 0.46–1.33 0.3697 155 1.31 0.60–2.86 0.4920
Prior rifaximin 153 0.56 0.32–0.98 0.0431 155 0.61 0.26–1.42 0.2528
CI, conﬁdence interval; HRS, hepatorenal syndrome; INR, international normalised ratio; MAP, mean arterial pressure; MELD,
model for end-stage liver disease; RR, relative risk.
* Baseline parameters for which data were available in both the OT-0401 and REVERSE studies were included in the analysis.
Table 3 | Pooled univariate logistic regression analysis of effects of baseline characteristics on 90-day transplant-free
survival and overall survival by treatment group (intent-to-treat population)
Baseline
parameter*
90-Day transplant-free survival 90-Day overall survival
Terlipressin Placebo Terlipressin Placebo
N RR 95% CI P value N RR 95% CI P value N RR 95% CI P value N RR 95% CI P value
Age <65
years
153 1.56 0.85– 2.86 0.1509 155 1.08 0.66–1.76 0.7560 153 1.54 0.84–2.82 0.1636 155 1.15 0.37–1.98 0.6140
Alcoholic
hepatitis
not present
153 1.21 0.84–1.74 0.3003 155 1.86 1.20–2.88 0.0058 153 1.19 0.83–1.72 0.3429 155 1.72 1.10–2.68 0.0168
Child–Pugh
score
143 0.95 0.88–1.02 0.1546 147 0.92 0.85–1.00 0.0591 143 0.94 0.87–1.01 0.0760 147 0.92 0.84–1.01 0.0807
INR 144 0.90 0.74–1.08 0.2570 148 0.91 0.76–1.10 0.3421 144 0.86 0.71–1.05 0.1428 148 0.91 0.75–1.11 0.3688
MAP 153 0.98 0.97–0.99 0.0009 154 1.00 0.99–1.01 0.9823 153 0.98 0.97–0.99 0.0004 154 1.00 0.99–1.01 0.7042
MELD
score
138 0.96 0.94–0.99 0.0012 140 0.99 0.97–1.01 0.3753 138 0.96 0.94–0.99 0.0011 140 0.99 0.97–1.02 0.4905
Serum
creatinine
153 0.82 0.72–0.93 0.0024 155 1.00 0.88–1.14 0.9931 153 0.82 0.72–0.94 0.0033 155 0.98 0.85–1.12 0.7590
Serum
sodium
153 1.00 0.98–1.02 0.6355 155 0.99 0.97–1.01 0.2980 153 0.99 0.97–1.01 0.5084 155 0.99 0.97–1.01 0.3957
Total
bilirubin
150 0.98 0.96–0.99 0.0038 150 0.99 0.98–1.00 0.1085 150 0.98 0.96–0.99 0.0040 150 0.99 0.98–1.01 0.2436
Male sex 153 1.10 0.82–1.49 0.5242 155 1.46 1.00–2.11 0.0477 153 1.14 0.84–1.55 0.4059 155 1.66 1.09–2.52 0.0175
No
precipitating
factor for
HRS
153 1.40 1.05–1.87 0.0232 155 1.30 0.96–1.74 0.0849 153 1.37 1.02–1.83 0.0358 155 1.34 0.98–1.84 0.0660
Prior rifaximin 153 1.24 0.93–1.65 0.1461 155 1.11 0.83–1.49 0.4875 153 1.21 0.90–1.62 0.2002 155 0.96 0.70–1.32 0.8169
Race group
(white vs.
non-white)
152 1.12 0.67–1.87 0.6704 155 1.96 0.85–4.55 0.1166 152 1.10 0.66–1.84 0.7081 155 1.84 0.79–4.27 0.1574
CI, conﬁdence interval; HRS, hepatorenal syndrome; INR, international normalised ratio; MAP, mean arterial pressure; MELD,
model for end-stage liver disease; RR, relative risk.
* Baseline parameters for which data were available in both the REVERSE and OT-0401 studies were included in the analysis.
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adequately power a study to demonstrate a survival
difference.
Lower MELD score, lower SCr, lower MAP, and lower
total bilirubin and absence of precipitating factors for
HRS at baseline were predictive of longer transplant-free
survival in the univariate analysis of the terlipressin
group. It is not surprising that those with less severe
liver disease and renal impairment had a higher chance
of surviving without liver transplantation. The ﬁndings
of lower MAP and absence of precipitating factors being
predictive of improved survival in the terlipressin group
were unexpected and merit further evaluation. For the
placebo group, only the absence of alcoholic hepatitis
and male sex were predictive of both longer transplant-
free survival and longer overall survival. While absence
of alcoholic hepatitis is a known predictive factor for
better survival,22 the ﬁnding of male sex as a predictor
should be examined further. Overall survival at day 90
was signiﬁcantly lower in females than in males; how-
ever, females receiving terlipressin showed a trend
towards improved survival compared with those receiv-
ing placebo, and the survival estimate was similar to that
for males.
Our observations regarding factors predictive of HRS
reversal and survival essentially conﬁrm what has been
observed in previous studies,22–27 with the exception of
the absence of a precipitating cause for HRS-1, absence
of prior rifaximin use in the terlipressin group, and male
sex in the placebo group – all new observations. The
absence of prior rifaximin use as a factor predictive of
HRS reversal in the terlipressin group is of interest; it is
possible that patients without prior rifaximin exposure
are less ill than those receiving rifaximin. However, the
effect of rifaximin exposure remained in the multivariate
model that adjusted for the commonly recognised factors
previously shown to be predictive of HRS reversal (e.g.
lower SCr, lower MELD score). Low patient numbers
restricted prior studies in their ability to explore multiple
predictive factors. Use of our larger pooled database,
derived from individual patient data, demonstrates the
value of such pooling to explore and identify previously
unreported factors that may be important in predicting
therapeutic response and survival in patients with HRS-
116, 19 and which require further study.
More patients experiencing HRS reversal with terli-
pressin plus albumin than with placebo plus albumin
were alive without renal replacement therapy at day 90
(76% vs. 55%, respectively). Thus, patients who achieve
HRS reversal with terlipressin plus albumin may have
better outcomes than patients who achieve HRS reversal
with albumin alone.
Previous studies have shown that for HRS reversal to
occur, a rise in MAP in response to treatment is
required, which was also observed in the current report.
The investigators proposed that the correlation between
changes in MAP and improvement in renal function
with terlipressin may be a result of terlipressin-induced
reduction in splanchnic vasodilation, which does not
occur with albumin alone.22
This pooled analysis has the usual limitations. The
studies were not designed for a pre-speciﬁed pooled
analysis. Although the studies were similar in patient
population, design, and dosing regimen, some differences
may have inﬂuenced the results and/or interpretation of
the results. These include the retrospective nature of the
analysis and unbalanced numbers of patients in some of
the subgroups. Nevertheless, we believe that our rigorous
approach using patient-level data analyses of the com-
bined populations from these large studies allows for a
higher degree of conﬁdence in the results observed
regarding treatment-related effects of terlipressin com-
pared with results observed via a standard meta-analysis.
In conclusion, in this pooled population of patients
with HRS-1, terlipressin plus albumin achieved a signiﬁ-
cantly higher rate of HRS reversal than placebo plus
albumin. More patients achieving HRS reversal with ter-
lipressin were alive without the need for renal replace-
ment therapy at 90 days compared with placebo. Our
ﬁndings conﬁrm that patients with HRS-1 who receive
terlipressin plus albumin achieve HRS reversal more fre-
quently, and have a greater degree of improvement in
renal function than patients who receive albumin alone.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article:
Data S1. The OT-0401 trial investigators.
Data S2. The REVERSE trial investigators.
Table S1. Pooled multivariate logistic regression analy-
sis of effects of baseline characteristics on HRS reversal
in the terlipressin group (intent-to-treat population).
Table S2. Pooled multivariate logistic regression analy-
sis of effects of baseline characteristics on 90-day trans-
plant-free survival by treatment group (intent-to-treat
population).
Table S3. Pooled multivariate logistic regression analy-
sis of effects of baseline characteristics on 90-day overall
survival by treatment group (intent-to-treat population).
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